The impact of rapid on-site evaluation (ROSE) on thyroid aspirates has been a matter of extensive debate. In the current study, the authors reviewed all thyroid fine-needle aspiration biopsies (FNABs) performed in their service in recent years to evaluate the impact of ROSE on final adequacy and diagnostic rates. METHODS: All ultrasoundguided FNABs of the thyroid performed between July 2015 and July 2017 were included retrospectively. ROSE was performed by experienced cytopathologists, with production of Romanowsky-stained slides for immediate evaluation.
INTRODUCTION
Over the past few decades, fine-needle aspiration biopsy (FNAB) has emerged as a valuable tool in the evaluation of thyroid nodules, and has proven to be a rapid, cost-effective, and reliable diagnostic procedure. 1, 2 Rapid on-site evaluation (ROSE) is a described technique in which a trained cytotechnologist/cytopathologist performs an immediate microscopic analysis of the cytological material after the aspiration. 3 This technique can be useful in various scenarios, increasing overall adequacy and optimizing the material for proper use
Cancer Cytopathology October 2018 in ancillary techniques such as immunohistochemistry, molecular analysis, flow cytometry, and microbiology. 4 However, the impact of ROSE on thyroid FNAB has been a matter of debate. Although some authors have reported a significant increase in specimen adequacy and a decrease in the mean number of needle passes required with ROSE, [5] [6] [7] [8] [9] [10] [11] others have advocated that its benefits are limited, with extended procedure times and higher costs. [12] [13] [14] In the current study, we retrospectively reviewed all thyroid FNABs performed in our service within the last 2 years to assess the impact of the incorporation of ROSE on the overall management, adequacy rate, and final diagnosis of the specimens.
MATERIALS AND METHODS
All ultrasound (US)-guided thyroid FNABs performed at the study institution between July 2015 (when ROSE was beginning to be used in our department) and July 2017 were included retrospectively in the current study. Data were extracted from the pathology reports and onsite registers, as well as from the final US report. Data recorded included the date of the procedure, the patient's sex and age, the location of the nodule, whether ROSE was performed, the number of needle passes needed, the type of cytology stains and preparations used, the final cytopathological report according to the first edition of The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC), 15 and subsequent histological diagnoses of the corresponding nodules (when available). Nodules resected without a prior FNAB diagnosis were not included in the current study.
US-Guided FNAB and ROSE
All FNABs were performed under US guidance in the radiology department of the study institution using a Toshiba Aplio500 US system (Toshiba Corporation, Tokyo, Japan) with a linear 6-megahertz to 12-megahertz transducer. Nearly all procedures were performed by radiology residents, with the assistance of experienced physicians. Aseptic techniques were performed routinely and local administration was used according to the patient's wishes. In a percentage of cases, ROSE was performed by certified cytopathologists in a pathology room inside the radiology department. Briefly, conventional smears were produced for each pass and stained with hematoxylin and eosin and/or Romanowsky staining (according to the pathologists' experience) and immediately analyzed under the microscope. In some cases, additional smears were fixed in ethanol for further Papanicolaou staining.
A cell block also was produced whenever it was deemed appropriate (eg, suspicion of metastatic disease to the thyroid, medullary thyroid carcinoma, or granulomatous disease) (Fig. 1) . Adequacy criteria followed those established by TBSRTC. 15 Whenever pathologists were not available or for those biopsies performed during off hours (after 7 pm or on weekends), ROSE was not performed. For procedures completed without ROSE, 3 dedicated passes were used as a default and all aspirated material was processed in liquid-based preparations (LBPs) (ThinPrep; Hologic Inc, Marlborough, Massachusetts) and later stained with conventional hematoxylin and eosin.
Statistical Analysis
All data analysis was performed using SPSS statistical software (IBM Corporation, Armonk, New York). The Pearson chi-square test was used when appropriate. A P value <.05 was considered to be statistically significant.
RESULTS
In total, US-guided FNAB material from 4649 thyroid nodules obtained over the course of 2 years was included in the current study. Of these cases, ROSE was performed in 3469 samples (74.6%) (ROSE group) and was not performed in 1180 samples (25.4%) (non-ROSE group). Of the 3469 specimens in the ROSE group, 421 (12.1%) were performed in 2015, 1909 (55%) were performed in 2016, and 1139 (32.8%) were performed in 2017. Of the FNAB samples from the non-ROSE group, 561 (47.5%) were performed in 2015, 579 (49.1%) were performed in 2016, and 40 (3.4%) were performed in 2017. Patients in the current study predominantly were female (85.4%), with a mean age of 53 years.
Complete Distribution of Cases and Risk of Malignancy by Each TBSRTC Category
Of all the nodules, 589 (12.7%) were deemed to be nondiagnostic (ND) on the final report. Benign cytology was reported in 3296 cases (70.9%), 417 cases (9%) demonstrated atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS), 77 cases (1.7%) were classified as follicular neoplasm or suspicious for follicular neoplasm (FN/SFN), 121 cases (2.6%) were classified as suspicious for malignancy (SM), and 149 cases (3.2%) were classified as malignant. The overall AUS/FLUS:malignant ratio was calculated at 2. 
Impact of ROSE
The use of ROSE was found to have a significant positive impact on the overall sample adequacy. From the final cytology report, the percentage of nodules deemed adequate for analysis was calculated at 93.4% (3241 of 3469 nodules) in the ROSE group and 69.4% (819 of 1180 nodules) in the non-ROSE group (P<.0001) ( Table 1 ). The mean number of needle passes necessary for an adequate diagnosis in the ROSE group was 1.48 ± 0.71 (median, 1.0 needle passes; range, 1-5 needle passes).
The ROM for each TBSRTC category in the ROSE group was as follows: 23 
DISCUSSION
In our experience, ROSE proved to be a valuable technique, and was capable of significantly improving our adequacy rates with a reduced mean number of needle passes required for each FNAB, with no significant impact observed on the assigned ROM for each TBSRTC category. To the best of our knowledge, the current study is one of the largest series to date regarding the impact of ROSE on the assessment of thyroid FNAB.
It has been widely advocated that institutions that use TBSRTC should regularly report their experiences, communicating the incidences and ROMs for each category to improve patient management. 16 Overall, the incidence rates in the current study are comparable to those of previously published meta-analyses in the literature. 17, 18 It is interesting to note that our AUS/ FLUS rate of 9% exceeds the provisional limiting goal of 7% suggested by TBSRTC in its first edition. 15 However, our numbers reflect several recent experiences by other authors, [19] [20] [21] [22] [23] [24] [25] which culminated in a newly proposed upper limit of 10% for this category in the latest edition of TBSRTC. 26 This usually is the case in centers with a high prevalence of malignant cases as is ours, which currently is the major cancer center in Latin America. As a matter of fact, regardless of the somewhat high rate of AUS/FLUS, the AUS/FLUS:malignant ratio in the current study did not exceed 3 (417/149 = 2.8), thereby supporting the quality of our practice. 27 Our reported ROMs for the ND and AUS/FLUS categories were greater than those proposed by the updated TBSRTC, but still comparable to previously reported experiences 17, 21, 22, [28] [29] [30] [31] regarding what can be affected directly and biased by the selection of clinically suspicious nodules for surgery and a higher incidence of malignancies in a cancer center environment. 22 The
ROMs for the malignant category reported herein (92.6% in the non-ROSE group and 93.8% in the ROSE group) were lower than those estimated by the first edition of TBSRTC (range, 97%-99%). 15 Possible reasons for this difference might be explained in part by the bias of working in a cancer center, in which both radiologists and pathologists tend to overcall suspicious nodules and therefore overrecommend surgery. The ND/unsatisfactory category includes cytology specimens that are inadequate/insufficient for diagnosis (ie, those samples that do not meet adequacy criteria and/or are obscured by preanalytical artifacts). 32 The incidences of this category have been reported to be as high as 18.8% in large series. 31, [33] [34] [35] Repeat aspiration usually is recommended for such nodules. 36 However, a new procedure is both time-consuming and costly for both patients and hospitals. 37 Therefore, efforts should be made to optimize specimen handling and adequacy. In the current study, the implementation of ROSE significantly increased the percentage of nodules deemed adequate for analysis in the final cytology report, with a final ND rate of only 6.6% in the ROSE group, a finding that is comparable to several experiences reported in the literature. [5] [6] [7] [8] [9] [10] [11] Unfortunately, no review of ND cases among the ROSE group was performed, and a clear cause of unsatisfactory results could not be determined from the collected data. A recent meta-analysis 8 emphasized the role of ROSE in significantly improving specimen adequacy, especially at institutions in which adequacy rates were low before the implementation of such a technique, as was the case in the study institution. The same authors also stressed the role of the level of experience and training of FNAB operators in their results, with experienced radiologists not found to benefit significantly from the addition of ROSE. 38 It is interesting to note that the clinicians performing the aspirations in the 2 groups studied herein had the same level of experience to avoid selection bias. Our experience with thyroid FNAB encompasses a perfect scenario for the practice of ROSE because the majority of FNABs performed at the study institution are done mainly by radiology residents with limited experience, and ROSE helps to establish a close liaison between the pathology and radiology teams, allowing for prompt correlation with imaging findings and contributing to a positive learning curve for all physicians involved. Notwithstanding, on-site assessment allows the cytopathologist, in selected cases, to collect further material for ancillary studies (eg, immunocytochemistry and flow cytometry) to improve diagnostic accuracy and ensure that sufficient quality material is collected for these additional techniques. 3 It is remarkable that ROSE encompasses a high percentage of our current thyroid FNAB practice, which differs from previously reported studies. 38, 39 As illustrated by the results of the current study, increasing trends toward the use of ROSE in our service were noted from 2015 to 2017. Experience gained through the years, allied with constant efforts toward developing an optimal on-site evaluation service and a close liaison between the cytopathologists and clinicians/ radiologists, may have contributed to the broad implantation of ROSE in the study institution.
To the best of our knowledge, the mean number of needle passes necessary to achieve an adequate diagnosis in thyroid FNAB specimens varies in the literature. 9, 13, [40] [41] [42] [43] [44] [45] Although some authors have advocated that routinely obtaining 3 passes with the limited use of ROSE may be the most cost-effective option, 40 multiple punctures usually are associated with greater patient discomfort and might lead to excessive blood contamination of the specimens, in addition to a greater incidence of complications from the procedure. In addition, the presence of the pathologist on site improves FNAB yield primarily in ND cases because there is immediate feedback regarding the causes of ND samples, such as excessive blood, calcification, or the exclusive representation of
Cancer Cytopathology October 2018 nonlesional tissue, which leads to a better orientation of the aspiration biopsy. Accordingly, in the current study, the implementation of ROSE was found to be associated with a mean number of 1.48 needle passes to acquire an adequate diagnosis, which is in contrast to the 3 punctures used as a default in the non-ROSE group. The current study data are comparable to those of a similar study that demonstrated that on-site assessment of thyroid FNABs substantially decreased the mean number of needle passes required, while at the same time increasing specimen adequacy. 9 In the current study, no significant differences were found with regard to the ROM for each TBSRTC category between the 2 groups analyzed (ROSE and non-ROSE). To the best of our knowledge, data regarding the impact of ROSE on the ROM of thyroid nodules are limited because the majority of published series have only a small number of cases with available histology outcomes to be significantly powered in this matter. 5, 11, 14, 43 In addition, specimen preparation does not appear to interfere in such a risk, 46 and therefore, the results of the current study may not have been hampered by the use of conventional smears in the ROSE group versus LBP in the non-ROSE specimens. In addition, because improvements in adequate sampling occurred equally among nodules with both malignant and benign histology, we believe it is unlikely that the use of ROSE would significantly alter the ROM of any TBSRTC categories. However, in the current study, only approximately 10.4% of the ROSE specimens presented histological correlation and larger studies analyzing such a relation therefore are warranted for a further discussion of the possible impact on the ROM for assigned Bethesda categories. Due to its retrospective nature, the current study had some limitations. First, we did not perform any cost-benefit analysis pertaining to the decrease in ND thyroid FNABs when ROSE was used. As previously mentioned by other authors, [12] [13] [14] we understand that ROSE can be very time-consuming and not cost-effective in some cases, particularly when it is performed by a cytopathologist versus a technician. These are not trivial issues and may represent some of the major hurdles to performing ROSE, especially for a busy thyroid FNAB service. One particular solution found in our service for the optimization of the cytopathologists' time is that the routine sign-out of cytological specimens is performed in the pathology room inside the radiology department (where ROSE is performed), and residents rotating in cytology bring their cases to the cytopathologist on service. Another limitation of the data presented herein is the large number of FNABs performed by radiology residents, which might have impacted our adequacy rates and not fully mirrored the impact of the implementation of ROSE in the study institution, because some cases remained classified as ND even with the on-site diagnostic assessment. Prospective studies might be useful to validate the results of the current study further, with a limitation of potential conflicting factors and a more accurate assessment of the impact of on-site assessment. Another potential limitation of the presented data is the referral bias resulting from the study institution being the major cancer center in Latin America, which might have contributed toward the increased ROM noted for some diagnostic categories.
One particular issue regarding the data presented in the current study is the use of conventional smears in the ROSE group compared with the use of LBPs in the non-ROSE group, which also might have had an impact on the adequacy rates in the 2 groups as well as on the final rendered diagnosis, and may have obscured the real impact of ROSE. However, to the best of our knowledge, data presented in the literature are in regard to whether LBPs have a positive or negative impact on specimen adequacy in thyroid FNABs. [46] [47] [48] [49] [50] [51] [52] Although originally designed to optimize specimen evaluation in gynecological cytology, 51 a recent large series found an association between LBP and a significantly higher percentage of inadequate specimens in comparison with conventional smears in thyroid aspirates. It is interesting to note that in the same study, the lack of ROSE associated with LBP was suggested as a potential source for the high inadequacy rates. 46 The experience presented herein is in keeping with these findings, and we speculate that known morphological artifacts associated with LBP, such as a decrease in colloid and alterations in the architecture of macrofollicles, ultimately may have contributed to a higher percentage of ND samples in the current study.
The results of the current study demonstrate that ROSE is an important procedure in thyroid FNAB, and significantly improves specimen adequacy with a combined decrease in the number of needle passes necessary to achieve an adequate cytological diagnosis. Therefore, we believe its broad implementation should be encouraged, especially in large referral teaching centers, in which Cancer Cytopathology October 2018 closer interactions among the clinical team members may translate into better patient management and consequently decrease the number of unnecessary additional invasive procedures or even early surgical interventions.
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